0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Arylsulfatase K inactivation causes mucopolysaccharidosis due to deficient glucuronate desulfation of heparan and chondroitin sulfate.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mucopolysaccharidoses comprise a group of rare metabolic diseases, in which the lysosomal degradation of glycosaminoglycans (GAGs) is impaired due to genetically inherited defects of lysosomal enzymes involved in GAG catabolism. The resulting intralysosomal accumulation of GAG-derived metabolites consequently manifests in neurological symptoms and also peripheral abnormalities in various tissues like liver, kidney, spleen and bone. As each GAG consists of differently sulfated disaccharide units, it needs a specific, but also partly overlapping set of lysosomal enzymes to accomplish their complete degradation. Recently, we identified and characterized the lysosomal enzyme arylsulfatase K (Arsk) exhibiting glucuronate-2-sulfatase activity as needed for the degradation of heparan sulfate (HS), chondroitin sulfate (CS) and dermatan sulfate (DS). In the present study, we investigated the physiological relevance of Arsk by means of a constitutive Arsk knockout mouse model. A complete lack of glucuronate desulfation was demonstrated by a specific enzyme activity assay. Arsk-deficient mice show, in an organ-specific manner, a moderate accumulation of HS and CS metabolites characterized by 2-O-sulfated glucuronate moieties at their non-reducing ends. Pathophysiological studies reflect a rather mild phenotype including behavioral changes. Interestingly, no prominent lysosomal storage pathology like bone abnormalities were detected. Our results from the Arsk mouse model suggest a new although mild form of mucopolysacharidose (MPS), which we designate MPS type IIB.

          Related collections

          Author and article information

          Journal
          Biochem J
          The Biochemical journal
          Portland Press Ltd.
          1470-8728
          0264-6021
          September 18 2020
          : 477
          : 17
          Affiliations
          [1 ] Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany.
          [2 ] Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA, U.S.A.
          [3 ] Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road, Athens, GA 30602, U.S.A.
          [4 ] Institute for Anatomy, University of Kiel, 24098 Kiel, Germany.
          [5 ] Laboratory of Biological Psychology, University of Leuven, 3000 Leuven, Belgium.
          [6 ] Industrial Organic Chemistry and Biotechnology, Faculty of Chemistry, Bielefeld University, 33615 Bielefeld, Germany.
          [7 ] Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
          [8 ] Department of Chemistry, University of Georgia, 315 Riverbend Road, Athens, GA 30602, U.S.A.
          [9 ] Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, and Bijvoet Center for Biomolecular Research, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
          Article
          226216 NIHMS1716142
          10.1042/BCJ20200546
          8261863
          32856704
          04b0c2f5-635c-482a-94b3-801922153dba
          © 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
          History

          desulfation,glycosaminoglycan degradation,lysosomal storage disorders,lysosomal sulfatases,mucopolysaccharidosis

          Comments

          Comment on this article